Therapeutics Metabolic and Endocrine Agents
RRM Academy Synopsis
Myo-inositol may improve ovulation and insulin resistance in PCOS
This review paper gathers results from earlier trials on myo-inositol. The trials cover insulin resistance, PCOS (also called PMOS), metabolic syndrome, and gestational diabetes. Myo-inositol helped ovulation and blood sugar markers in women with PCOS in these trials.
Key Findings
- Obese women with PCOS took D-chiro-inositol for eight weeks. 86% ovulated, versus 27% on placebo.
- In a 12-week trial of 50 overweight women with PCOS, myo-inositol restored regular cycles in those with irregular or missing periods. Folic acid alone did not.
- In another trial, 61.7% of women with PCOS ovulated after taking myo-inositol. Among those who did not respond, adding a fertility drug raised ovulation to 72.2%.
- Among pregnant women with a close relative who had type 2 diabetes, myo-inositol lowered the gestational diabetes rate to 6.0%, versus 15.3% on placebo.
- In an 80-woman trial of postmenopausal women with metabolic syndrome, myo-inositol led 8 women (20%) to no longer meet the criteria for it. Only 1 in the control group did.
Interpretation
This review paper gathers findings from earlier trials and reviews on myo-inositol, published in a heart journal. Group sizes in the cited trials run from about 50 to 80 women, where given. Myo-inositol was linked with better ovulation and blood sugar markers in women with PCOS, a lower gestational diabetes rate in women at higher risk, and fewer metabolic syndrome diagnoses after menopause. The findings support larger trials of myo-inositol for these conditions.
RRM Context
Insulin resistance often stops ovulation in PCOS. PCOS is also called PMOS. PMOS stands for polyendocrine metabolic ovarian syndrome. Restorative Reproductive Medicine treats insulin resistance as a root cause of PCOS.
Abstract not indexed.
Topics
Keywords
atrial fibrillation, carotid artery diseases, peripheral vascular diseases
